# AK112 and AK104 With or Without Chemotherapy in Advanced Non-small Cell Lung Cancer

> **NCT05904379** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Akeso** · enrollment: 233 (estimated)

## Conditions studied

- Advanced Non-small-cell Lung Cancer

## Interventions

- **DRUG:** AK112
- **DRUG:** AK104
- **DRUG:** Carboplatin
- **DRUG:** paclitaxel
- **DRUG:** pemetrexed
- **DRUG:** Docetaxel

## Key facts

- **NCT ID:** NCT05904379
- **Lead sponsor:** Akeso
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-07-13
- **Primary completion:** 2026-06-30
- **Final completion:** 2027-01-31
- **Target enrollment:** 233 (ESTIMATED)
- **Last updated:** 2026-03-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05904379

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05904379, "AK112 and AK104 With or Without Chemotherapy in Advanced Non-small Cell Lung Cancer". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT05904379. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*